Russia's Medtech Looks For Chain Reaction After Philips Partnership Deal

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

Russia's health care sector has been under strain, suffering budgets cuts and repercussions from the ongoing sanctions. In the midst of this, plans to reinforce the local medtech industry received a boost recently when global top 10 manufacturer Philips Healthcare committed funds to embarking on new R&D locally and to further partnerships in Russia.

Russia map close up with magnifier

[Editors' note:This is the first of three Medtech Insight pieces based on interviews with Moscow-based IMEDA. Upcoming themes will be: Progress in establishing the Eurasian Economic Union principles for medical technology regulation; and Interventions on pricing and the tricky task of forming relationships with the Russian regulator Roszdravnadzor.]

Russia's public-procurement restrictions, introduced partly as a reaction to the EU-US sanctions imposed in 2014, are intended by the authorities...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Europe

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 
• By Natasha Barrow

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 
• By Brian Bossetta

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

More from Geography

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 
• By Brian Bossetta

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

 
• By Natasha Barrow

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.